Zobrazeno 31 - 40
of 247
pro vyhledávání: '"Masaaki Kawahara"'
Autor:
Takeharu Yamanaka, Hiromi Wada, Masaaki Kawahara, Nobuyuki Kondo, Toshiaki Manabe, Shinji Atagi, Hiroshi Date, Seiki Hasegawa, Fumihiro Tanaka, Ryo Miyahara
Publikováno v:
Oncology research and treatment. 39(10)
Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a standard procedure for the pathological evaluation of the mediastinal nodal (N2) status of lung cancer; however, its feasibility in potentially operable pat
Autor:
Tomonobu Koizumi, Masaaki Kawahara, Kazuhiro Asami, Nobutoshi Morozumi, Akio Morikawa, Shinji Atagi, Akihiro Tsukadaira, Shingo Ameshima, Kazuya Hirai
Publikováno v:
Clinical Lung Cancer. 12:387-392
Efficacy of first-line gefitinib for elderly epidermal growth factor receptor mutated patients with lung adenocarcinoma is uncertain. This study was aimed to investigate efficacy of gefitinib for such population. The primary endpoint was response rat
Autor:
Koji Takeda, Toshiyuki Sawa, Hisao Uejima, Fumio Imamura, Masaaki Kawahara, Hideo Saka, Kazuhiko Nakagawa, Soichiro Yokota, Yasuo Iwamoto, Hiroshi Semba, Takashi Seto, Toyoaki Hida, Nobuyuki Katakami, Shinzoh Kudo, Kayoko Tsujino, Nobuyuki Yamamoto, Yasumasa Nishimura, Miyako Satouchi, Yasutaka Chiba, Masahiro Fukuoka
Publikováno v:
Journal of Clinical Oncology. 28:3739-3745
Purpose This phase III trial of concurrent thoracic radiotherapy (TRT) was conducted to compare third-generation chemotherapy with second-generation chemotherapy in patients with unresectable stage III non–small-cell lung cancer (NSCLC). Patients a
Autor:
Ryusei Saito, Yosihito Maruyama, Jason A. Zell, Akihide Matsumura, Atsuhisa Tamura, Argyrios Ziogas, Shimao Fukai, Sai-Hong Ignatius Ou, Masaaki Kawahara, Tomoya Kawaguchi
Publikováno v:
Journal of Thoracic Oncology. 5(7):1001-1010
BackgroundWe previously reported that Asian ethnicity was a favorable prognostic factor for overall survival (OS) in non-small cell lung cancer (NSCLC). In this study, we performed a combined data analysis from a Japanese Cancer Registry and a region
Autor:
K Komuta, K Nakano, Masahiro Tsuboi, Masaaki Kawahara, Toshiro Yonei, Mitsuo Fukushima, Tomoya Kawaguchi, Koichi Minato, Satoshi Teramukai, Y Kishida, Kaoru Kubota, T. Mio, Y Fujita, Kiyoyuki Furuse, S. Atagi, K Shibata
Publikováno v:
British Journal of Cancer
Background: Neutropenia is a common adverse reaction of chemotherapy. We assessed whether chemotherapy-induced neutropenia could be a predictor of survival for patients with non-small-cell lung cancer (NSCLC). Methods: A total of 387 chemotherapy-na
Autor:
Toshirou Yonei, Kiyoyuki Furuse, Masanori Fukushima, Tomoya Kawaguchi, Philip C. Mack, Satoshi Teramukai, Kazuhiko Shibata, Koichi Minato, Shun-ichi Isa, Masaaki Kawahara, Kenji Hayashibara, Yoshinobu Ohsaki
Publikováno v:
Journal of Thoracic Oncology. 4:1104-1110
Background The Japan-Multinational Trial Organization (JMTO) lung cancer (LC) 0003 was a prospective randomized phase III trial investigating advanced non-small cell lung cancer comparing paclitaxel (P) plus carboplatin (C) versus vinorelbine (V), ge
Publikováno v:
Cancer Science. 100:316-321
TZT-1027 is a novel synthetic dolastatin 10 derivative that inhibits tubulin polymerization. A phase I study was conducted to determine the maximum tolerated dose (MTD) of TZT-1027, and to assess its pharmacokinetic profile in Japanese patients with
Autor:
Noriko Hoshihara-Fukuda, Mayumi Oka, Noriko Arai, Mayo Yamamoto, Masaaki Kawahara, Yuko Miyazaki
Publikováno v:
JAPANESE ORTHOPTIC JOURNAL. 38:125-132
Autor:
Akira Yokoyama, Toyoaki Hida, Kaoru Matsui, Nobuyuki Katakami, Koshiro Watanabe, Masaaki Kawahara, Masahiro Fukuoka, Nagahiro Saijo, Kaoru Kubota, Yutaka Nishiwaki, Kazuhiko Nakagawa, Kazumasa Noda, Tomohide Tamura, Koji Takeda
Publikováno v:
Journal of Thoracic Oncology. 3(12):1439-1445
IntroductionThe aim of this study was to evaluate the efficacy and safety of Erlotinib in Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available tumor biopsy samples were analyzed to examine relationships between biom
Phase I/II Study of Docetaxel and S-1 in Patients with Previously Treated Non-small Cell Lung Cancer
Autor:
Yoko Kusunoki, Ryusei Saito, Shimao Fukai, Masaaki Kawahara, Hikotaro Komatsu, Akihito Kubo, Minoru Takada, Yoshio Tomizawa, Katsuyuki Yumine, Kazutaka Uehira, Kyoiti Okishio, Shinji Atagi, Tomoya Kawaguchi
Publikováno v:
Journal of Thoracic Oncology. 3:1012-1017
Introduction The aim of this study was to determine and evaluate the recommended dose of docetaxel in combination with a novel oral 5-fluorouracil analogue S-1 and evaluate the efficacy and safety in patients with previously treated non-small cell lu